Introduction Alectinib demonstrated clinical efficacy and an acceptable safety profile in two
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …

Objectives A pooled analysis of two open-label phase II studies of alectinib (NP28673
[NCT01801111] and NP28761 [NCT01871805]) demonstrated clinical activity in patients …

LBA9008 Background: Alectinib, a TKI targeting ALK, has shown robust efficacy in crizotinib-
naïve/resistant ALK+ NSCLC. J-ALEX showed superiority of alectinib 300mg BID vs …

Abstract Objectives The J-ALEX study compared the efficacy and safety of alectinib with
crizotinib in Japanese patients with advanced ALK-positive non-small-cell lung cancer …

Purpose Alectinib is an anaplastic lymphoma kinase (ALK)–specific kinase inhibitor that
seems to be effective against non–small-cell lung cancer (NSCLC) with a variety of ALK …

Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …

8019 Background: Crizotinib is an approved treatment for patients (pts) with ALK-rearranged
(ALK+) NSCLC. However, progression on crizotinib, particularly in the CNS, frequently …

Background The ALEX study demonstrated significantly improved progression-free survival
(PFS) with alectinib versus crizotinib in treatment-naive ALK-positive non-small-cell lung …

Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic
lymphoma kinase (ALK), showed promising efficacy and tolerability in the single-arm phase …

Purpose Alectinib has shown activity in the CNS in phase I and II studies. To further evaluate
this activity, we pooled efficacy and safety data from two single-arm phase II studies …